What Researchers Did
Researchers retrospectively analyzed the effectiveness of hyperbaric oxygen therapy (HBOT) in 33 patients suffering from hemorrhagic cystitis caused by viral infections or radiation.
What They Found
Of the 33 patients, 27.3% had radiation-induced hemorrhagic cystitis (HC) and 72.7% had viral HC. HBOT resulted in improved macroscopic hematuria for 81.8% (n=27) of patients, and HC did not recur in 57.6% (n=19) over three years of follow-up. A significant correlation was found between the degree of hematuria and the number of HBOT sessions required (p=0.0025).
What This Means for Canadian Patients
Canadian patients experiencing hemorrhagic cystitis, particularly after radiation therapy or viral infections, may consider hyperbaric oxygen therapy as a potential treatment. This therapy could help reduce bleeding symptoms and lower the risk of recurrence, offering a practical benefit for managing this challenging condition.
Canadian Relevance
While no direct Canadian connection was identified for the study authors or location, hyperbaric oxygen therapy is recognized by Health Canada for delayed radiation injury, which encompasses radiation-induced hemorrhagic cystitis.
Study Limitations
The retrospective nature of this study means it cannot definitively prove cause and effect and may be subject to inherent biases.